Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-06-28
2011-06-28
Anderson, James D (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S049000
Reexamination Certificate
active
07968565
ABSTRACT:
The present invention relates to SNS-595 and methods of treating cancer using the same.
REFERENCES:
patent: 4261989 (1981-04-01), Sasaki et al.
patent: 5817669 (1998-10-01), Tomita et al.
patent: 6171857 (2001-01-01), Hendrickson
patent: 6291643 (2001-09-01), Zou et al.
patent: 6570002 (2003-05-01), Hardwick et al.
patent: 6641810 (2003-11-01), Gold
patent: 6670144 (2003-12-01), Craig et al.
patent: 6696483 (2004-02-01), Singh
patent: 7211562 (2007-05-01), Rosen et al.
patent: 2003/0165887 (2003-09-01), Reed
patent: 09-221424 (1997-08-01), None
patent: 11-349565 (1999-12-01), None
patent: WO02/20500 (2002-03-01), None
patent: WO2004/085418 (2004-10-01), None
patent: WO2005/089756 (2005-09-01), None
Oxford Textbook of Oncology, 1995, vol. 1, pp. 445-453.
Tomitra, Kyoji Synthesis and Structure-Activity Relationships of Novel 7-Substituted 1,4-Dihydro-4-oxo-1-(2-thiazolyl)-1, 8-naphthyridine-3-carboxylic Acids as Antitumor Agents. Part 1, J. Med. Chem. 2002, vol. 45, pp. 5564-5575, 2002.
Tsuzuki, Yasunori et al., “Efficient stereospecific synthesis of (S,S)-3-methoxy-4-methylaminopyrrolidine”, Tetrahedron: Asymmetry, vol. 12, pp. 1793-1799, 2001.
Tsuzuki, Yasunori et al., Synthesis and Structure-Activity Relationships of Novel 7-Substituted 1,4-Dihydro-4-oxo-1-(2-thiazoly1)-1,8-naphthyrldine-3-carboxylic Acids as Antitumor Agents. Part 2, vol. 47, pp. 2097-2109, 2004.
Jacob, Leonard S., “National Medical Series for Independent Study: Pharmacology”, Fourth Edition, Chapter 11, pp. 253-274, 1996.
Patrick Therasse, et al., “New Guidelines to Evaluate the Response to Treatment in Solid Tumors”, Journal of the National Cancer Institute, vol. 92, No. 3, Feb. 2, 2000.
Goodman & Gilman, The Pharmacological Basis of Therapeutics, McGraw-Hill Medical Publishing Division, Tenth Edition, pp. 1404-1411, 2001.
The Merck Manual (1999), p. 988.
Arbitrario, et al.. “SNS-595 A Novel S-Phase Active Cytotoxic Acts Synergistically With Cytarabine to Reduce Bone Marrow Cellularity and Circulating Neutrophils,”American Society of Hematologyconference, 2006.
Stockett et al., poster presentation at EORTC, 2009.
Chiba, et al., “Practical Synthesis of AG-7352, Optically Active New Antitumor Agent.” Abstract, 218thACS National Meeting, Aug. 22-26, 1999.
Evanchik, et al., “Non-Clinical Admet, PK, and Biological Activity of SNS-595, a Novel Cell Cycle Inhibitory Antineoplastic Agent.” Drug metabolism reviews, Marcel Dekker,New York, NY, US, vol. 36, No. SUPPL1, Aug. 2004 (2004-2008), p. 103. XP008073741.
Kashimoto, et al., “Antitumor Activity of a Novel Quinolone Analog AG-7352 in Human Xenograft Models of Leukemia or Drug-Resistant Tumors and in an Experimental Metastatic Tumor Model.” Proceedings of the Annual Meeting of the American Association for Cancer Research. New York, NY, vol. 42, Mar. 2001, p. 102-Abstract 553. XP008073722.
Lawrence, et al., “SNS-595, a Novel S-Phase Active Cytotoxic, Demonstrates Pharmacologic Properties Appropriate for the Treatment of Advanced Hematologic Malignancies.” Blood, vol. 106, No. 11, Part 2, Nov. 2005, p. 2378. XP008073743.
Lawrence, et al., “SNS-595, A Novel S-Phase Active Cytotoxic, Exhibits Potent In Vitro and In Vivo Activies, and Has the Potential for Treating Advanced Hematoloic Malignancies.” Proceedings of the Annual Meeting of the American Association for Cancer Research, New York, NY, Vo. 47, Apr. 2006, p. 1110.
Nakano, et al., “Antitumor Antitumor Activity of a Novel Quinolone DNA Topoisomerase II Inhibitor AG-7352.” Proceedings of the Annual Meeting of the American Association for Cancer Research, New York, NY, vol. 40, Mar. 1999, p. 115-Abstract 767. XP008073720.
Sato, et al., “In Vivo Antitumor Activity of a Novel Quinolone Analogue AG-7352 Against a Borad-Spectrum of Cancers and Drug-Resistant Human Cancers.” Abstract, 11thNCI-EOARTC-AACR symposium on new drugs in cancer therapy, Nov. 7-10, 2000.
Thirion, et al., “Interest of investigating p53 status in breast cancer by four different methods.” Oncology Reports, vol. 9, No. 6, Nov. 2002, pp. 1167-1172.
Tomita, Kyoji Synthesis and Structure-Activity Relationships of Novel 7-Substituted 1-4-Dihydro-4-oxo-1-(2-thiaolyl)-1, 8-naphthyrdine-3-carboxylic Acids as Antitumor Agents. Part 1, J. Med Chem. 2002, vol. 45 pp. 5564-5575, 2002.
Tomita, et al., “Synthesis and Antitumor Activity of Novel 7-Substituted 1,4-Dihydro-4-Oxo-1-(2-Thiazolyl)-1,8-Naphthyridine-3-Carboxylic Acids.” Abstracts of Papers American Chemical Society, vol. 217, No. 1-2, 1999, p. MEDI 249.
Tsuzuki, et al., “Practical Synthesis of (3S,4S)-3-Methoxy-4-Methylaminopyrrolidine.” Tetrahedron: Asymmetry 12(2001) 2989-2997.
Tsuzuki, et al., “Process Research of a Novel Quinolone Antitumor Agent, AG-7352.” English Abstract, The Japanese Society for Process Chemistry, 2004 Summer Symposium.
Tsuzuki, et al., “Synthesis and Structure—Activity Relationships of 3-Substitued 1, 4-Dihydro-4-Oxo-1-(2-Thiazolyl)-1, 8-Naphthridines as Novel Antitumor Agents.” Bioorganic & Medicinal Chemistry Letters 14 (2004): 3189-3193.
Tsuzuki, et al., “Synthesis of Optically Active Amine at C-7 Position of New Antitumor Agent AG-7352.” Abstract, Molecular Chirality Conference, 1999.
Wright, et al., “SNS-595 Has Synergistic Activity in Vitro with DNA Damaging Agents and Antimetabolites.” Proceedings of the Annual Meeting of the American Association for Cancer Research, New York, NY, vol. 47, Apr. 2006, p. 504. XP001199686.
JP09-221424 English Abstract, 1997.
JP11-349565 English Abstract, 1999.
Arkin Michelle
Hyde Jennifer
Walker Duncan
Wright Jasmin
Anderson James D
Jones Day
Sunesis Pharmaceuticals, Inc.
LandOfFree
Therapeutic combinations comprising... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic combinations comprising..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic combinations comprising... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2705466